Qol Holdings (3034) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
21 Jul, 2026Executive summary
Achieved record-high sales and profits for the first quarter ended June 30, 2025, with net sales up 17.5% to ¥71,730 million and operating profit up 23.2% to ¥3,592 million, driven by growth in dispensing sales, new AG products, and increased stake in DAIICHI SANKYO ESPHA.
EBITDA increased 23.2% year-over-year to ¥5,958 million, reflecting strong operational performance.
Profit attributable to owners of parent surged 120.2% to ¥1,856 million, with EPS up 118.8% to ¥49.43.
Acquisition of an additional 29% stake in DAIICHI SANKYO ESPHA in April 2025 raised ownership to 80%, significantly impacting consolidated results and equity.
Financial highlights
Net sales rose 17.5% year-over-year to ¥71,730 million; operating profit up 23.2% to ¥3,592 million; ordinary profit up 22.6% to ¥3,635 million.
Gross profit reached ¥10,386 million, up from ¥9,149 million year-over-year.
Profit attributable to owners of parent surged 120.2% to ¥1,856 million; EPS climbed to ¥49.43.
Comprehensive income was ¥2,214 million, up 54.1% year-over-year.
Gross profit margin slightly decreased as cost of sales rose 18.2%.
Outlook and guidance
Full-year net sales forecast at ¥280,000 million (up 6.1% year-over-year), with 1Q progress at 25.6%.
Operating profit forecast at ¥15,500 million (up 15.1%), with 1Q progress at 23.2%.
Net income per share forecast at ¥186.35, with 1Q progress at 26.5%.
Profit attributable to owners of parent forecasted at ¥7,000 million (up 35.5%).
No changes to previously announced financial forecasts.
Latest events from Qol Holdings
- Net sales and operating profit surged on consolidation, but net profit declined on higher non-controlling interests.3034
Q2 202521 Jul 2026 - Net sales rose 40.6% and operating profit increased 55.6% on strong segment and consolidation gains.3034
Q1 202521 Jul 2026 - Record sales and profit achieved; robust outlook and higher dividends forecast.3034
Q4 202521 Jul 2026 - Record-high profit and sales driven by pharmaceutical manufacturing and DAIICHI SANKYO ESPHA.3034
Q2 202621 Jul 2026 - Record-high profit and sales driven by pharmaceutical manufacturing and BPO growth, with ROE at 12.9%.3034
Q4 202621 Jul 2026 - Record sales and operating profit achieved, but parent profit declined due to higher costs and minority interests.3034
Q3 202521 Jul 2026 - Record-high sales and profit attributable to owners, with strong segment growth and stable outlook.3034
Q3 202621 Jul 2026